When applied to the dynamic <sup>18</sup>F-FDG measurement of colon cancer, the proposed algorithm accurately identified densely vascularized regions from the rest of the tumor.
Among clinically relevant genes, NBN and SMUG1 were identified as independent prognostic factors that predicted poor survival in colon cancer patients.
This suggests that the pretreatment SUV<sub>max</sub> in <sup>18</sup>F-FDG PET/CT is a useful tool to help predict survival outcome in patients with colon cancer and unresectable liver metastases and may significantly distinguish between patients with low and high levels of Beclin-1 expression (AUC = 0.809, 95% CI: 0.670-0.948, p = 0.001).
These colon carcinoma lesions selectively accumulated [<sup>18</sup>F]fluorodeoxyglucose ([<sup>18</sup>F]FDG) and [<sup>18</sup>F]fluoroacetate ([<sup>18</sup>F]FACE) at high levels, reflecting elevated carbohydrate and fatty acid metabolism in these tumors.